Related Experiment Video

Updated: Dec 10, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.0K

Low-dose versus high-dose methylprednisolone for children with severe Mycoplasma pneumoniae pneumonia (MCMP): Study

Baoping Xu1, Xiaoxia Peng2, Yao Yao1

  • 1China National Clinical Research Center for Respiratory Diseases Department of Respiratory Medicine Beijing Children's Hospital Capital Medical University, National Center for Children's Health Beijing China.

Pediatric Investigation
|August 28, 2020
PubMed
Abstract

Insights

This study compares low-dose versus high-dose methylprednisolone for severe Mycoplasma pneumoniae pneumonia (MPP) in children. It aims to determine optimal glucocorticoid dosage to reduce long-term lung damage from severe MPP.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Severe Mycoplasma pneumoniae pneumonia (MPP) can lead to lasting lung issues despite macrolide treatment.
  • Glucocorticoid therapy may improve outcomes, but optimal dosing for severe MPP remains unclear.

Purpose of the Study:

  • To investigate the efficacy of low-dose versus high-dose methylprednisolone in mitigating long-term pulmonary sequelae in pediatric severe MPP.
  • To provide evidence-based guidance for clinical management of severe MPP in children.

Main Methods:

  • A randomized, single-blind, multicenter trial involving 402 pediatric patients with severe MPP.
  • Patients received either low-dose (2 mg/kg/d) or high-dose (10 mg/kg/d) methylprednisolone for 3 days, followed by a 12-day taper, alongside azithromycin.
  • Primary outcome: incidence of atelectasis, bronchiectasis, or bronchiolitis obliterans at 6 months; secondary outcomes include recovery time, lesion absorption, and length of stay.

Main Results:

  • This section is not yet available as the study is ongoing.
  • The study is designed to collect comprehensive data on short-term and long-term outcomes.

Conclusions:

  • This is the first randomized clinical trial comparing low-dose and high-dose methylprednisolone for severe pediatric MPP.
  • Results will inform clinical practice regarding optimal glucocorticoid use for severe MPP, aiming to reduce long-term pulmonary complications.
Keywords:
ChildrenGlucocorticoidsSevere Mycoplasma pneumoniae pneumonia

More Related Videos

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice07:43

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

9.4K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
610
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
148
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
637
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
102